Business Standard

Sunday, December 22, 2024 | 11:01 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

DRL launches Avigan for mild Covid-19 infections at Rs 99 a tablet

Drug to be imported from Japan for time being, India manufacturing to start soon

covid, coronavirus, vaccine, drug, pharma, medicine, cure
Premium

DRL forged a global licensing deal with Fujifilm Toyama Chemical for the exclusive rights to manufacture, sell and distribute Avigan in India

Sohini Das Mumbai
Hyderabad-based Dr Reddy's Laboratories (DRL) launched the innovator brand of favipiravir Avigan, an antiviral used to treat mild to moderate Covid-19 patients, in India. Priced at Rs 99 per tablet, the drug would be imported from Japan now. 

DRL plans to manufacture the drug here in India soon. M V Ramana, CEO, Branded Markets (India and Emerging Markets), DRL said that the process of technology transfer is on with Fujifilm and DRL will be able to start manufacturing in India within a quarter or so. The company is also planning to ship it to patients who call its helpline directly

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in